Category: Encision Inc.
Colorado medical device maker Encision announces the death of CEO Fred Perner, 59, who passed away from a heart attack last week; Wall Street sends ECIA shares down 17%.
Boston Scientific launches its BackStop kidney stone treatment, licensed from Pluromed, in the U.S. and certain international markets; also, Siemens lands 3rd year defense contract worth up to $1.9 billion; Bruker Corp. nabs all shares of SkyScan for an undisclosed amount; Viking expects 40% sales growth for Q1 2012; Smith & Nephew acquires LifeModeler for an undisclosed amount; Wound Care Innovations signs exclusive N.A.
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
3M's 4th-quarter profits beat The Street as it affirms its 2012 guidance, but shares stay flat; also, Hill-Rom's Q1 earnings slide 7%; Getinge sees 2011 profits rise 11% despite sales slide; ResMed's Q2 sales, earnings rise; Uroplasty pares Q3 losses on doubled sales; Encision swings to Q3 losses; and EnteroMedics' Q4, 2011 losses rise.
3M Co. (NYSE:MMM) beat expectations for its 4th-quarter profits and affirmed its guidance for 2012, but Wall Street remained unmoved, with shares staying flat in this morning's trading.
3M Co.'s third-quarter sales rose 9.6 percent but profits slipped 1.6 percent nevertheless, with the conglomerate's health care division posting sales and operating income increases; also, Essilor's Q3 sales rise 6.4%; Teleflex profits soar during Q3; sales up, earnings down for ResMed; Enteromedics' operating losses more than double; Cynosure's sales nearly double but losses increase almost 75%; Encision's sales rise, losses soar; and Young Innovations' profits tick up despite flat sales.
Shares of 3M Co. (NYSE:MMM) lost nearly 6 percent today after the conglomerate reported a 1.6 percent profit slide for the third quarter and slashed its sales and earnings guidance for 2011.
3M reported profits of $1.09 billion, or $1.52 per share, on sales of $7.53 billion. That's a top-line increase of 9.6 percent compared with Q3 2010. Wall Street analysts expected $1.61 per share for the latest quarter.